Search results:
General Information
| Gene_Symbol | Gene_ID | Gene_Name | Chromosome | Alias |
|---|---|---|---|---|
| MYC | 4609 | v-myc avian myelocytomatosis viral oncogene homolog | 8 | c-Myc, bHLHe39, MYCC |
- Evidence
- Gene
- mRNA
- CDS
- Protein
- PTM
- Enzyme
- PPi
- Pathway
- Structural
- Domain
- Ontology
- SNP
- Drug
- External Links
Evidence Information
| Pubmed ID | Year | Sample Information | Techniques | Mechanism | Fold Change | Remark |
|---|---|---|---|---|---|---|
| 24503701 | 2014 | Cell line : - Source : Department of Anatomical Pathology, Royal North Shore Hospital, Sydney Sample Type : Case control study No. of Sample : 1421 Stage : - | Immunohistochemistry | Up-regulation | - | Myc status as determined by IHC alone can be used to predict overall survival in patients with CRC undergoing surgical resection. MYC over-expression was found in 980 (69%) of CRCs and was associated with tumor stage and DNA mismatch repair/BRAF status. |
| 23613397 | 2013 | Cell line : - Source : - Sample Type : Parafin embeded CRC tissue sample No. of Sample : 60 Stage : - | Microarray, Immunohistochemistry | Up-regulation | - | c-MYC overexpression is correlated with progressive disease - due to colon adenocarcinoma dedifferentiation - inhibition of its activity combined with h-TERT regulated expression is a new target for novel therapeutic regimens. |
Gene Details
| Gene Type | protein coding |
|---|---|
| Gene Family | Basic helix-loop-helix proteins |
| Description | The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. | Chromosome | 8 |
| Location | 8q24 |
| Start | 127736069 |
| End | 127741434 |
| Strand | + |
| Gene Sequence | Download Select all |
| Length | 5366 |
| OMIM ID | 190080 |
| HGNC ID | HGNC:7553 |
| Unigene ID | Hs.202453 |
| Ensembl ID | ENSG00000136997 |
| PharmGKB ID | - |
mRNA Information
| mRNA ID | NM_002467.4 |
|---|---|
| Exon | join(526..555,2180..2951,4328..4890) | mRNA Sequence | Download Select all |
| Length | 2379 |
CDS Information
| Location | join(1..555,2180..2951,4328..5366) |
|---|---|
| CDS Sequence | Download Select all |
| CCDS ID | CCDS6359.2 |
Protein Information
| Protein ID | NP_002458.2 |
|---|---|
| Protein Name | v-myc avian myelocytomatosis viral oncogene homolog |
| Molecular Wt. (Da) | 50434 |
| Protein Sequence | Download Select all |
| Length | 454 |
| Uniprot ID | P26583 |
| Ensembl Protein ID | ENSP00000296503 |
Post-translational Modification Information (Source : HPRD)
| Residue | Type | site |
|---|---|---|
| T | Glycosylation | 73 |
| S | Phosphorylation | 77 |
| S | Phosphorylation | 86 |
| T | Phosphorylation | 73 |
| T | Phosphorylation | 73 |
| T | Phosphorylation | 73 |
| S | Phosphorylation | 359 |
| S | Phosphorylation | 363 |
| T | Phosphorylation | 365 |
| K | Acetylation | 163 |
| S | Phosphorylation | 21 |
| S | Phosphorylation | 79 |
| S | Phosphorylation | 88 |
| S | Phosphorylation | 176 |
Enzyme Information
No matching records could be found.
PPi Information
(Click to view network : Source STRING) View
| Interactant Gene ID (Source: HPRD) | Gene Symbol | HPRD ID | Ref Seq ID | Technique | References |
|---|---|---|---|---|---|
| 672 | BRCA1 | 218 | NP_009231.2 | in vitro;in vivo;yeast 2-hybrid | 978 843 712 646 176 |
| 983 | CDK1 | 302 | NP_001777.1 | in vivo | 1748630 |
| 1050 | CEBPA | 296 | NP_004355.2 | in vitro;in vivo | 12873812 |
| 1051 | CEBPB | 1801 | NP_005185.2 | in vitro;in vivo | 12873812 |
| 1387 | CREBBP | 2534 | NP_004371.2 | in vitro;in vivo;yeast 2-hybrid | 12776737 |
| 1999 | ELF3 | 3722 | NP_004424.3 | in vitro;in vivo | 1651323 |
| 2033 | EP300 | 4078 | NP_001420.2 | in vivo | 1 277 673 717 157 250 |
| 2932 | GSK3B | 5418 | NP_002084.2 | in vitro;in vivo | 11 877 389 824 752 400 000 000 |
| 2962 | GTF2F1 | 1803 | NP_002087.2 | in vitro | 8755740 |
| 3320 | HSP90AA1 | 777 | NP_001017963.2 | in vivo | 12644583 |
| 4149 | MAX | 1113 | NP_002373.3 | in vitro;in vivo | 2 006 410 170 723 080 000 000 000 000 000 000 000 000 000 000 |
| 4292 | MLH1 | 390 | NP_000240.1 | in vitro;in vivo;yeast 2-hybrid | 12584560 |
| 4801 | NFYB | 1794 | NP_006157.1 | in vitro;in vivo | 11282029 |
| 5371 | PML | 23 | NP_150241.2 | in vitro;in vivo | 15735755 |
| 5604 | MAP2K1 | 1469 | NP_002746.1 | in vitro | 7957875 |
| 5894 | RAF1 | 1265 | NP_002871.1 | in vitro | 9315742 |
| 5925 | RB1 | 1574 | NP_000312.2 | in vivo | 7838535 |
| 5933 | RBL1 | 312 | NP_002886.2 | in vivo | 8076603 |
| 5970 | RELA | 1241 | NP_068810.3 | in vivo | 12027803 |
| 6502 | SKP2 | 3256 | NP_005974.2 | in vivo | 17157259 |
| 6667 | SP1 | 1796 | NP_612482.2 | in vivo | 11274368 |
| 6908 | TBP | 2511 | NP_003185.1 | in vivo | 15723054 |
| 9014 | TAF1B | 5363 | NP_005671.2 | in vivo | 15723054 |
| 57650 | KIAA1524 | 11151 | NP_065941.2 | in vitro;in vivo | 1 947 095 417 632 050 |
| 84875 | PARP10 | 15100 | NP_116178.2 | in vitro;in vivo | 15674325 |
Pathway Information
| Pathway Name | Pathway ID |
|---|---|
| Acute myeloid leukemia | hsa05221 |
| Bladder cancer | hsa05219 |
| Cell cycle | hsa04110 |
| Central carbon metabolism in cancer | hsa05230 |
| Chronic myeloid leukemia | hsa05220 |
| Colorectal cancer | hsa05210 |
| Endometrial cancer | hsa05213 |
| Epstein-Barr virus infection | hsa05169 |
| ErbB signaling pathway | hsa04012 |
| Hepatitis B | hsa05161 |
| Hippo signaling pathway | hsa04390 |
| HTLV-I infection | hsa05166 |
| Jak-STAT signaling pathway | hsa04630 |
| MAPK signaling pathway | hsa04010 |
| MicroRNAs in cancer | hsa05206 |
| Pathways in cancer | hsa05200 |
| PI3K-Akt signaling pathway | hsa04151 |
| Proteoglycans in cancer | hsa05205 |
| Signaling pathways regulating pluripotency of stem cells | hsa04550 |
| Small cell lung cancer | hsa05222 |
| TGF-beta signaling pathway | hsa04350 |
| Thyroid cancer | hsa05216 |
| Thyroid hormone signaling pathway | hsa04919 |
| Transcriptional misregulation in cancer | hsa05202 |
| Wnt signaling pathway | hsa04310 |
Structure Information
| PDB ID | 1A93 |
|---|---|
| Resolution | |
| Method | SOLUTION NMR |
| Chains | A |
| Molecule | MYC PROTO-ONCOGENE PROTEIN |
| Model | View |
Domain Information
| ID | Location | Description |
|---|---|---|
| cd00083 | 355-411 | HLH |
| cl00081 | 355-411 | HLH superfamily |
| pfam01056 | 1-345 | Myc_N |
| cl03082 | 1-345 | Myc_N superfamily |
| smart00353 | 360-412 | HLH |
| pfam00010 | 355-407 | HLH |
| pfam02344 | 408-439 | Myc-LZ |
| cl03551 | 408-439 | Myc-LZ superfamily |
Ontology Information
| HPRD ID | 2612 |
|---|---|
| Molecular Class | Transcription factor |
| Molecular Function | Transcription regulator activity (GO:0030528) |
| Biological Process | Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism (GO:0019219) |
Drug Information
| Uniprot ID | DrugBank ID | Name | Type |
|---|---|---|---|
| P01106 | DB08813 | Nadroparin | SmallMoleculeDrug |